ResMed Inc. (RMD)
ResMed: Digital Health Drives Q2 Growth
ResMed (RMD 1.89%), a leader in sleep apnea and respiratory care solutions, reported strong fiscal 2025 second-quarter earnings on Thursday, Jan. 30. The medical device company outperformed analyst consensus forecasts with adjusted EPS of $2.43 topping the $2.32 estimate and revenue of $1.282 billion beating the expected $1.266 billion.
Compared to Estimates, ResMed (RMD) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ResMed (RMD) Tops Q2 Earnings and Revenue Estimates
ResMed (RMD) came out with quarterly earnings of $2.43 per share, beating the Zacks Consensus Estimate of $2.30 per share. This compares to earnings of $1.88 per share a year ago.
ResMed beats quarterly profit estimates on demand for sleep disorder devices
ResMed beat Wall Street estimates for second-quarter profit on Thursday, driven by strong demand for its devices used to manage sleep apnea, a common sleep disorder.
ResMed (RMD) Earnings Expected to Grow: Should You Buy?
ResMed (RMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
ResMed (RMD) is an Incredible Growth Stock: 3 Reasons Why
ResMed (RMD) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why ResMed (RMD) is a Strong Growth Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
ResMed Gains 37.8% in a Year: What's Driving the Stock?
RMD's shares gain on the back of robust mask and device sales growth. However, the unfavorable macroeconomic scenario is concerning.
Will ResMed (RMD) Beat Estimates Again in Its Next Earnings Report?
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why ResMed (RMD) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Sleep Apnea Device Maker Stocks Slide on FDA Ruling for Eli Lilly's Zepbound
Shares of ResMed (RMD) and Inspire Medical Systems (INSP) fell Monday as the companies behind products to treat sleep apnea faced a new threat from weight-loss drugs.
